Synapse - Adult Leukemia

Results (3720)

Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity

Meeting Abstract

Kunimoto, H.; Meydan, C.; Nazir, A.; Shank, K.; Maher, R.; Rapaport, F.; Pronier, E.; Melnick, A.; Levine, R. L.; Shih, A. H.
Blood (2016)

Fulltext@MSK | Save

ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): Final results of the SWOG/Alliance/ECOG S0535 trial

Meeting Abstract

Lancet, J. E.; Moseley, A.; Komrokji, R. S.; Coutre, S. E.; DeAngelo, D. J.; Tallman, M. S.; Litzow, M.; Othus, M.; Appelbaum, F. R.
Blood (2016)

Fulltext@MSK | Save

Combined treatment with lenalidomide (LEN) and epoetin alfa (EA) is superior to lenalidomide alone in patients with erythropoietin (Epo)-refractory, lower risk (LR) non-deletion 5q [Del(5q)] myelodysplastic syndrome (MDS): Results of the E2905 Intergroup Study - an ECOG-ACRIN Cancer Research Group study, grant CA180820, and the National Cancer Institute of the National Institutes of Health

Meeting Abstract

List, A. F.; Sun, Z.; Verma, A.; Bennett, J. M.; McGraw, K. L.; Nardelli, L. A.; Maciejewski, J. P.; Altman, J. K.; Cheema, P.; Claxton, D. F.; more...
Blood (2016)

Fulltext@MSK | Save

Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR-ABL, reveals significant and durable responses in patients with CML-chronic phase with failure of prior TKI therapy

Meeting Abstract

Hughes, T. P.; Goh, Y. T.; Ottmann, O. G.; Minami, H.; Rea, D.; Lang, F.; Mauro, M. J.; DeAngelo, D. J.; Talpaz, M.; Hochhaus, A.; more...
Blood (2016)

Fulltext@MSK | Save

JAK1 as a convergent regulator of hematopoietic stem cell function and stress hematopoiesis

Meeting Abstract

Kleppe, M.; Spitzer, M. H.; Li, S.; Dong, L.; Papalexi, E.; Hill, C.; De Groote, S.; Keller, M.; Koppikar, P.; Rapaport, F.; more...
Blood (2016)

Fulltext@MSK | Save

Tyrosine kinase inhibitor (TKI) switching patterns during the first 12 months in simplicity, an observational study of chronic-phase chronic myeloid leukemia (CP-CML) patients (Pts) in routine clinical practice

Meeting Abstract

Goldberg, S.; Michallet, M.; Hehlmann, R.; Zyczynski, T.; Foreman, A.; Calimlim, B.; Paquette, R.; Simonsson, B.; Gambacorti, C.; Cortes, J. E.; more...
Blood (2016)

Fulltext@MSK | Save

Pembrolizumab, a PD-1 inhibitor, in patients with myelodysplastic syndrome (MDS) after failure of hypomethylating agent treatment

Meeting Abstract

Garcia-Manero, G.; Tallman, M. S.; Martinelli, G.; Ribrag, V.; Yang, H.; Balakumaran, A.; Chlosta, S.; Zhang, Y.; Smith, B. D.
Blood (2016)

Fulltext@MSK | Save

Multicolor flow cytometry and multi-gene next generation sequencing are complimentary and highly predictive for relapse in acute myeloid leukemia following allogeneic hematopoietic stem cell transplant

Meeting Abstract

Getta, B. M.; Devlin, S.; Maloy, M. A.; Mohanty, A.; Arcila, M.; Tallman, M. S.; Levine, R. L.; Giralt, S. A.; Roshal, M.
Blood (2016)

Fulltext@MSK | Save

Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL

Meeting Abstract

Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
Blood (2016)

Fulltext@MSK | Save

Frequent clinical overlap of histiocytic neoplasms and WHO-classified myeloid malignancies leads to functional insights into the cell-of-origin of histiocytoses

Meeting Abstract

Durham, B. H.; Yoshimi, A.; Papo, M.; Chung, Y. R.; Ozkaya, N.; Ganzel, C.; Dogan, A.; Hyman, D. M.; Park, C. Y.; Rampal, R. K.; more...
Blood (2016)

Fulltext@MSK | Save